English

Interim Report Vigmed Holding AB (publ) 1 January – 31 March 2017

Report this content

First quarter: 1 January-31 March 2017

  • Sales for the first quarter amounted to SEK 1.3 (2.0) million.
  • Operating result in the first quarter amounted to SEK -8.6 (-7.0) million.
  • Cash flow from operating activities during the first quarter amounted to SEK -9.9 (-10.8) million.
  • On 31 March 2017 cash and cash equivalents amounted to SEK 5.9 (53.5) million.

Significant events during the first quarter

The investigation initiated in the fourth quarter of 2016 regarding the sterilisation method’s impact on SWiTCH FEP products resulted in a withdrawal of the products from the market in the beginning of January.

Vigmed was granted its first Chinese patent for its needle protecting solution found in the product lines CLiP® and SWiTCH.

In March 2014, the company issued 755,000 warrants to key employees of the subsidiary Vigmed AB, with the right to subscribe for the same number of shares in Vigmed Holding AB at an exercise price of SEK 21.8 per share (recalculated exercise price after the latest rights issue in December 2015). The warrants were issued on market terms. During the subscription period 15 January 2017 until 31 January 2017, no warrants were exercised.

On 27 February 2017, Greiner Bio-One GmbH (GBO), an Austrian limited company with Greiner Holding AG as a group parent company, offered a public offer to the shareholders of Vigmed Holding AB (Vigmed) to transfer all shares in Vigmed to GBO for a consideration of SEK 1,00 in cash for each share in Vigmed. Vigmed’s independent bid committee recommended in a statement on 27 February 2017 Vigmed’s shareholders to accept the offer.

 

For further information contact:
Chairman of the Board Sten Dahlborg, +46 708-369 419
CEO Henrik Olsen, +46 763-497 364

This information is information which Vigmed Holding AB (publ) is obliged to publish under the EU Market Abuse Regulation     and the Securities Market Act. The information was provided by the above contact person’s auspices, for publication on 30 May 2017 at 3 pm.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor.Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor 

Tags:

Vigmed AB

Documents & Links